AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21804338
Drug: Laughter therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laughter therapy (60 min, twice a week for 2 weeks, total of 4 sessions)
Trial: 19782873
Drug: Non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical treatment (including hand therapy and ultrasound)
Trial: 14964742
Drug: Targeted biologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted biologic therapies
Trial: 10743698
Drug: L-arginine 3
RxNorm normalized name: Natrol Men's Health L-Arginine 3,000mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine 3 x 500 mg/day
Trial: 2205997
Drug: Regional intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional intravenous block
Trial: 30924165
Drug: Lenograstim at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenograstim at 10 μg/kg/day for at least 4 consecutive days (early collection group)
Trial: 30924165
Drug: Lenograstim at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenograstim at 10 μg/kg/day for at least 4 consecutive days (late collection group)
Trial: 25296654
Drug: DHEA capsule
DrugBank: Prasterone sulfate (DB05804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA capsule 75 mg/day for at least 12 weeks before egg collection
Trial: 22725663
Drug: Curcumin 1000
RxNorm normalized name: Radiance Platinum Turmeric Curcumin 1000mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin 1000 mg capsules once daily for 14 days
Trial: 2210021
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion (2 U bolus injection; 111 mU/min for 2 hours)
Trial: 28740204
Drug: Topically administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically administered autologous APOSEC (12.5 × 106 PBMCs)
Trial: 28740204
Drug: Topically administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically administered autologous APOSEC (25 × 106 PBMCs)
Trial: 28740204
Drug: Topically administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically administered APOSEC (both doses)
Trial: 25670636
Drug: Rosuvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (40 mg on admission, followed by 20 mg/day)
Trial: 25670636
Drug: Rosuvastatin and
RxNorm normalized name: rosuvastatin and ramipril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin and No statin treatment (control group)
Trial: 21334753
Drug: Simvastatin 80
RxNorm normalized name: simvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 80 mg (S80)
Trial: 16749654
Drug: SIMVA 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIMVA 20 mg
Trial: 14996777
Drug: Treatment guidelines
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment guidelines tailored for the elderly with care management
Trial: 8988065
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg tramadol in extensive metabolizers
Trial: 8988065
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg tramadol in poor metabolizers
Trial: 6652642
Drug: Oral propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propranolol 80 mg, twice daily for 5 days
Trial: 6652642
Drug: Oral metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metoprolol 100 mg, twice daily for 5 days
Trial: 6652642
Drug: Intravenous propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propranolol 10 mg
Trial: 6652642
Drug: Intravenous metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoprolol 20 mg
Trial: 30902820
Drug: BI 655064
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 655064 (120 mg weekly for 12 weeks)
Trial: 27636757
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy in addition to conventional treatment
Trial: 27636757
Drug: Only photodynamic
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only photodynamic therapy
Trial: 22994867
Drug: Psychoacoustic Advanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoacoustic Advanced Combination Encoder (PACE)
Trial: 22994867
Drug: Advance Combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advance Combination Encoder (ACE)
Trial: 19888030
Drug: Control (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (weekly vaginal assessment for Bishop score)
Trial: 17513664
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg hyperbaric bupivacaine
Trial: 17513664
Drug: 6.0 mg
RxNorm normalized name: Dimethicone 6.0 mg in 30 mL TOPICAL CREAM [Clapiel Revital Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.0 mg hyperbaric bupivacaine
Trial: 15159466
Drug: Mirtazapine 15
RxNorm normalized name: mirtazapine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine 15 to 30 mg/day
Trial: 27585447
Drug: Activities of
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activities of daily living (control group)
Trial: 23382519
Drug: High frequency
RxNorm normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL SOLUTION [enMotion Foam High Frequency Use]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High frequency (HF) SPG stimulation for treatment
Trial: 15118469
Drug: Ahmed drainage
RxNorm normalized name: PLEURX DRAINAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ahmed drainage implant
Trial: 1979522
Drug: Acyclovir (ACV)
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyclovir (ACV) 50 mg/kg once a week in a 3-hour infusion with 1 g oral probenecid
Trial: 27835050
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose of Chromium Picolinate (600 mcg/day)
Trial: 27835050
Drug: Insulin AUC
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin AUC (all groups)
Trial: 27835050
Drug: Insulin Sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin Sensitivity Index (ISI) (all groups)
Trial: 23864641
Drug: 5% CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% CO2 inhalation during LBNP
Trial: 9305478
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate 400 mg b.d. + clarithromycin 250 mg b.d. + metronidazole 500 mg b.d. (group A)
Trial: 9305478
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate 400 mg b.d. + clarithromycin 250 mg b.d. + metronidazole 250 mg q.d.s (group B)
Trial: 3095522
Drug: High aluminum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High aluminum load from experimental high calcium- and phosphorus-containing PN solution (306 +/- 26 micrograms/L) for up to 6 weeks
Trial: 3095522
Drug: Lower aluminum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower aluminum load from standard Ca-P solutions (144 +/- 16 micrograms/L)
Trial: 29517580
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (topical prostaglandins)
Trial: 29517580
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (topical beta blockers and carbonic anhydrase inhibitors)
Trial: 29517580
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no intraocular pressure-lowering medications)
Trial: 22746337
Drug: Yohimbine 5
RxNorm normalized name: yohimbine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine 5 mg
Trial: 15195048
Drug: Oral spray
RxNorm normalized name: Oral Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral spray lubricant applied before bedtime
Trial: 8254783
Drug: Ciprofloxacin 100
RxNorm normalized name: ciprofloxacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 100 mg at night for 6 months
Trial: 3303785
Drug: Conventional injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional injection therapy (CIT)
Trial: 2178389
Drug: Acorns (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acorns (25 g carbohydrate portion)
Trial: 2178389
Drug: Corn (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn (25 g carbohydrate portion)
Trial: 26024575
Drug: Lycopene in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene in capsule
Trial: 23121338
Drug: Hybrid therapy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid therapy: pantoprazole 40 mg/b.i.d. and amoxicillin 1 g/b.i.d. for 14 days plus 500 mg clarithromycin and 500 mg tinidazole, both twice daily for the last 7 days
Trial: 23121338
Drug: Sequential therapy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy: 40 mg pantoprazole/b.i.d. for 10 days and 1 g amoxicillin/b.i.d. for the first 5 days, followed by 500 mg clarithromycin/b.i.d. and 500 mg tinidazole/b.i.d. for the last 5 days
Trial: 19094067
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion (4.8 pmol/kg per min)
Trial: 17409891
Drug: Radiation plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation plus chemotherapy
Trial: 11160760
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of memantine
Trial: 9283163
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no epidural morphine)
Trial: 7509261
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of urtica/pygeum preparation (300 mg of Urtica dioica root extract combined with 25 mg of Pygeum africanum bark extract)
Trial: 7509261
Drug: Half the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half the standard dose of urtica/pygeum preparation
Trial: 3080461
Drug: Isocal supplemented
RxNorm normalized name: ISOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocal supplemented with NaCl to give 2 g Na/day (Diet B)
Trial: 3080461
Drug: Unsupplemented Isocal
RxNorm normalized name: ISOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsupplemented Isocal providing 1 g Na/day (Diet C)
Trial: 3080461
Drug: Mixed foods
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed foods (3-6 g Na/day) orally before gastrostomy (Diet A)
Trial: 21962092
Drug: Flunisolide HFA
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flunisolide HFA (2 puffs twice daily, 85 μg/puff)
Trial: 16327016
Drug: ET(A)-receptor antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ET(A)-receptor antagonist (BQ-123)
Trial: 31085788
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B liposomal gel
Trial: 31085788
Drug: Paromomycin sulfate
RxNorm normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paromomycin sulfate liposomal gel
Trial: 31085788
Drug: Daylight option
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daylight option of photodynamic therapy
Trial: 16297052
Drug: Tacrolimus monotherapy
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus monotherapy (TACRO)
Trial: 16297052
Drug: Tacrolimus plus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus plus steroids (TACRO + ST)
Trial: 16297052
Drug: Tacrolimus monotherapy
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus monotherapy (real-TACRO)
Trial: 16297052
Drug: Tacrolimus plus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus plus steroids (real-TACRO + ST)
Trial: 9569054
Drug: FEP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEP regimen (epirubicin 35 mg/m², etoposide 120 mg/m², cisplatin 45 mg/m²)
Trial: 9569054
Drug: FEP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEP regimen plus low-dose GM-CSF (150 microg/day on days 5-14)
Trial: 285045
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy regimen A
Trial: 285045
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy regimen B
Trial: 31312931
Drug: Oral uracil-tegafur
RxNorm normalized name: tegafur / uracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral uracil-tegafur (UFT)
Trial: 1907566
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate (100-200 mg daily)
Trial: 6136346
Drug: Purified allergen
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified allergen preparation from Timothy pollen (Timothy N)
Trial: 27807040
Drug: Combined intervention
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intervention of albendazole (single dose), zinc (14 days), and daily multiple micronutrient powder for 24 weeks
Trial: 22928615
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) applied on the right side of jaws (GaAlAs LLLT, 670 nm, 5 mW, 14 min/day for five consecutive days)
Trial: 16162784
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL of 4% lidocaine (160 mg)
Trial: 16162784
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL of saline solution as placebo
Trial: 16162784
Drug: Combined sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined sedation with 5 mg of IV hydrocodone and midazolam
Trial: 14550328
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (home-based early intervention with weekly visits for 6 months and biweekly visits from 6 to 18 months)
Trial: 9378845
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch (day 2)
Trial: 9378845
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch followed by nicotine gum (day 3)
Trial: 9378845
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch followed by nicotine gum and cigarette smoking (day 4)
Trial: 3946752
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (clindamycin and gentamicin)
Trial: 30165984
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fluticasone furoate and vilanterol
Trial: 30165984
Drug: Highest quintile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest quintile of cardiac troponin (≥7.7 ng/l)
Trial: 20620737
Drug: Ticagrelor (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180 mg load, then 90 mg twice daily; n=57)
Trial: 20620737
Drug: Clopidogrel (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (600 mg load, then 75 mg daily; n=54)
Trial: 19166421
Drug: Metronidazole-containing therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole-containing therapy (lansoprazole 15 mg once-daily, amoxicillin 500 mg twice-daily, metronidazole 250 mg twice-daily)
Trial: 19166421
Drug: Clarithromycin-containing therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin-containing therapy (lansoprazole 15 mg once-daily, amoxicillin 500 mg twice-daily, clarithromycin 250 mg once-daily)
Trial: 11833038
Drug: Transdermal 50
RxNorm normalized name: Banamine Transdermal 50 MG/ML Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 50 microg/d estradiol for 12 weeks (estrogen replacement therapy [ERT])
Trial: 11833038
Drug: Transdermal 50
RxNorm normalized name: Banamine Transdermal 50 MG/ML Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 50 microg/d estradiol for 12 weeks (ERT)
Trial: 10028105
Drug: Episodic or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Episodic or suppressive treatment
Trial: 10028105
Drug: Type-specific serological
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type-specific serological tests for HSV antibodies
Trial: 1672878
Drug: Levocabastine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocabastine (0.5 mg/ml), nasal spray, twice in each nostril, four times a day
Trial: 28922068
Drug: Flaxseed lignan-enriched
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed lignan-enriched complex (600 mg SDG)
Trial: 23340005
Drug: Low-dose itraconazole
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose itraconazole (200 mg/day)
Trial: 23340005
Drug: High-dose itraconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose itraconazole (600 mg/day)
Trial: 17348989
Drug: Dutasteride 0.5
RxNorm normalized name: dutasteride 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride 0.5 mg/day for 12 months
Trial: 15096079
Drug: Oral treatment
RxNorm normalized name: Other agents for local oral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment with 2 mg of risperidone plus 2 mg of lorazepam
Trial: 15096079
Drug: Intramuscular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular treatment with 5 mg of haloperidol plus 2 mg of lorazepam
Trial: 9835726
Drug: Intramuscular route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular route for postoperative analgesia (POA)
Trial: 2924690
Drug: Diuretic combination
RxNorm normalized name: atenolol and other diuretics, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic combination (hydrochlorothiazide + triamterene)
Trial: 29630702
Drug: Bupropion hydrochloride,
RxNorm normalized name: BuPROPion Hydrochloride, 75 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion hydrochloride, 150 mg twice daily
Trial: 29630702
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy, 21‐mg/d patch with tapering
Trial: 27655905
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy (6 courses of modified infusional fluorouracil and folinic acid with oxaliplatin before and after surgery)
Trial: 27655905
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy (modified infusional fluorouracil and folinic acid with oxaliplatin; 12 cycles)
Trial: 16905398
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy with family unit including the patient
Trial: 16905398
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy with a group of relatives
Trial: 10788287
Drug: Social support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social support intervention administered by nurse and peer advisors
Trial: 8706290
Drug: 3% saline
RxNorm normalized name: dextrose 2.5%-0.3% saline (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% saline infusion followed by oral water load (10 ml/kg over 3 minutes)
Trial: 1829098
Drug: Steroid suppressive
RxNorm normalized name: Buckley's Cough Suppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid suppressive agents (aminoglutethimide, ketoconazole, metyrapone) for 2 months
Trial: 1829098
Drug: Not applicable
RxNorm normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable (discontinuation of other psychotropic drugs)